Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors.
Cutaneous melanoma
DNA mismatch repair proteins
Immune checkpoint inhibitors
Ipilimumab
Microsatellite instability
Mismatch repair deficiency
Nivolumab
Pembrolizumab
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
11
03
2022
accepted:
29
03
2022
pubmed:
15
4
2022
medline:
8
3
2023
entrez:
14
4
2022
Statut:
ppublish
Résumé
To investigate the protein expression of DNA mismatch repair (MMR) proteins in patients with cutaneous melanoma (CM) under immune checkpoint inhibitor (ICI) therapy. Immunohistochemistry was performed on tumor tissue for MMR proteins MLH1, MSH2, MSH6, and PMS2 in 50 metastatic CM patients treated with ICI (ipilimumab, nivolumab, pembrolizumab). Best overall response (BOR) rate was 48% (24/50). Reduced MMR protein expression (nuclear expression in < 80% of tumor cells) was observed in 8 patients (16%). Compared to other clinical parameters, baseline neutrophil/lymphocyte ratio and reduced intratumoral MMR protein expression (P = 0.0033) were determined as the only parameters significantly associated with favorable BOR. However, in this small study population, reduced MMR protein expression did not reach statistical significance in multivariate analysis. Reduced MMR protein expression is observed in CM and might predict favorable BOR in patients treated with ICI, as was observed for other entities. However, these findings need to be substantiated in larger patient cohorts.
Identifiants
pubmed: 35419731
doi: 10.1007/s00432-022-04002-4
pii: 10.1007/s00432-022-04002-4
pmc: PMC9984342
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
MutL Protein Homolog 1
EC 3.6.1.3
Mismatch Repair Endonuclease PMS2
EC 3.6.1.3
MutS Homolog 2 Protein
EC 3.6.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241-1247Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
World J Surg Oncol. 2017 Jun 26;15(1):116
pubmed: 28651545
Cancers (Basel). 2021 Feb 06;13(4):
pubmed: 33561950
Melanoma Res. 2016 Dec;26(6):545-550
pubmed: 27623135
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Cancers (Basel). 2021 May 21;13(11):
pubmed: 34063983
Cancer Discov. 2022 Apr 1;12(4):1088-1105
pubmed: 34983745
Acta Dermatovenerol Croat. 2018 Dec;26(4):341-343
pubmed: 30665488
Front Immunol. 2018 Jun 28;9:1474
pubmed: 30002656
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
Pathologica. 2020 Dec;112(4):178-183
pubmed: 32893846
Hum Pathol. 2004 Dec;35(12):1543-8
pubmed: 15619215
Am J Clin Pathol. 2014 Jul;142(1):121-32
pubmed: 24926095
Oncotarget. 2018 Jan 3;9(15):12452-12470
pubmed: 29552325
Cancer Discov. 2021 Jul;11(7):1844-1859
pubmed: 33653693
Science. 2019 May 3;364(6439):485-491
pubmed: 31048490
Front Oncol. 2021 May 20;11:639085
pubmed: 34094921
Transl Gastroenterol Hepatol. 2021 Jan 05;6:12
pubmed: 33409406
Curr Oncol. 2021 Aug 27;28(5):3316-3322
pubmed: 34590599
Mol Clin Oncol. 2020 Jan;12(1):3-8
pubmed: 31814971
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
Cancers (Basel). 2021 Sep 16;13(18):
pubmed: 34572886